[go: up one dir, main page]

MA34519B1 - Anticorps anti-fap et procédés d'utilisation - Google Patents

Anticorps anti-fap et procédés d'utilisation

Info

Publication number
MA34519B1
MA34519B1 MA35725A MA35725A MA34519B1 MA 34519 B1 MA34519 B1 MA 34519B1 MA 35725 A MA35725 A MA 35725A MA 35725 A MA35725 A MA 35725A MA 34519 B1 MA34519 B1 MA 34519B1
Authority
MA
Morocco
Prior art keywords
methods
fap antibodies
fap
antibodies
relates
Prior art date
Application number
MA35725A
Other languages
English (en)
Inventor
Marina Bacac
Anne Freimoser-Grundschober
Ralf Hosse
Christian Klein
Ekkehard Moessner
Valeria G Nicolini
Pablo Umana
Original Assignee
Roche Glycart Ag
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44629814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag, Hoffmann La Roche filed Critical Roche Glycart Ag
Publication of MA34519B1 publication Critical patent/MA34519B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre la protéine d'activation des fibroblastes (FAP) et des procédés d'utilisation de ceux-ci.
MA35725A 2010-08-13 2011-08-09 Anticorps anti-fap et procédés d'utilisation MA34519B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172842 2010-08-13
PCT/EP2011/063648 WO2012020006A2 (fr) 2010-08-13 2011-08-09 Anticorps anti-fap et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA34519B1 true MA34519B1 (fr) 2013-09-02

Family

ID=44629814

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35725A MA34519B1 (fr) 2010-08-13 2011-08-09 Anticorps anti-fap et procédés d'utilisation

Country Status (36)

Country Link
US (5) US9011847B2 (fr)
EP (2) EP2603530B1 (fr)
JP (4) JP5793568B2 (fr)
KR (2) KR101780131B1 (fr)
CN (2) CN105884898B (fr)
AR (2) AR082629A1 (fr)
AU (1) AU2011288487B2 (fr)
BR (1) BR112013003361B8 (fr)
CA (1) CA2806021C (fr)
CL (2) CL2013000369A1 (fr)
CO (1) CO6670523A2 (fr)
CR (2) CR20180142A (fr)
DK (1) DK2603530T3 (fr)
EA (2) EA034742B1 (fr)
EC (1) ECSP13012440A (fr)
ES (1) ES2655616T3 (fr)
HR (1) HRP20172004T1 (fr)
HU (1) HUE036077T2 (fr)
IL (2) IL224355B (fr)
LT (1) LT2603530T (fr)
MA (1) MA34519B1 (fr)
MX (2) MX386437B (fr)
MY (2) MY175341A (fr)
NO (1) NO2603530T3 (fr)
NZ (2) NZ703653A (fr)
PE (2) PE20131209A1 (fr)
PH (2) PH12013500159B1 (fr)
PL (1) PL2603530T3 (fr)
PT (1) PT2603530T (fr)
RS (1) RS56702B1 (fr)
SG (1) SG187746A1 (fr)
SI (1) SI2603530T1 (fr)
TW (2) TWI599578B (fr)
UA (2) UA113712C2 (fr)
WO (1) WO2012020006A2 (fr)
ZA (2) ZA201600551B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2483310T3 (pl) 2009-09-29 2015-01-30 Roche Glycart Ag Bispecyficzne przeciwciała agonistyczne dla receptora śmierci
US9011847B2 (en) * 2010-08-13 2015-04-21 Roche Glycart, AG Anti-FAP antibodies and methods of use
ES2883371T3 (es) 2011-02-10 2021-12-07 Roche Glycart Ag Polipéptidos de interleucina 2 mutantes
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013026839A1 (fr) 2011-08-23 2013-02-28 Roche Glycart Ag Anticorps bispécifiques spécifiques pour les antigènes d'activation des lymphocytes t et un antigène tumoral et procédés d'utiliation correspondants
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
UA116192C2 (uk) 2011-08-23 2018-02-26 Рош Глікарт Аг Активуюча т-клітини біоспецифічна антигензв'язуюча молекула
ES2848732T3 (es) * 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
EP2882774B1 (fr) 2012-08-08 2018-10-03 Roche Glycart AG Protéines de fusion de l'interleukine-10 et leurs utilisations
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2879768A1 (fr) 2012-10-08 2014-04-17 Roche Glycart Ag Anticorps exempts de fc comprenant deux fragments fab et procedes d'utilisation
KR20150122203A (ko) 2013-02-26 2015-10-30 로슈 글리카트 아게 T 세포 활성화 이중특이적 항원 결합 분자
WO2014131694A1 (fr) 2013-02-26 2014-09-04 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN106061997A (zh) * 2014-02-06 2016-10-26 豪夫迈·罗氏有限公司 白介素‑10免疫缀合物
RS58149B1 (sr) 2014-02-06 2019-02-28 Hoffmann La Roche Fuzioni proteini interleukina-2 i njihova upotreba
GB201402006D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
WO2015164723A1 (fr) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Procédés et compositions pour le traitement du cancer du sein métastatique et d'autres cancers dans le cerveau
EP3142750B1 (fr) 2014-05-13 2020-07-01 The Trustees Of The University Of Pennsylvania Compositions comprenant un virus adéno-associé exprimant des constructions à double anticorps et leurs utilisations
SG11201702805TA (en) * 2014-10-08 2017-05-30 Hoffmann La Roche Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
HUE054122T2 (hu) 2014-11-14 2021-08-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
HRP20221083T1 (hr) 2014-11-20 2022-11-25 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
WO2016110598A1 (fr) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Nouveaux anticorps anti-protéine d'activation des fibroblastes (fap) et utilisations de ceux-ci
GB201500875D0 (en) 2015-01-19 2015-03-04 Philogen Spa Antibodies for treatment and diagnosis
CN107207579B (zh) 2015-03-31 2022-02-25 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
RU2761115C1 (ru) 2015-10-02 2021-12-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора
BR112018001530A2 (pt) 2015-10-02 2018-11-06 Hoffmann La Roche anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica
CN106928368B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种FAP纳米抗体Nb57
EP3231813A1 (fr) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Molécules de liaison d'antigène costimulantes trimères contenant un ligand de la famille du tnf
EP3243836A1 (fr) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
EP3243832A1 (fr) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1
CN106018780B (zh) * 2016-05-17 2017-12-26 扬州大学 一种基于f1蛋白的检测4型禽腺病毒抗体的间接免疫荧光试剂盒
EP3468963B1 (fr) 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Composes carboxamide de dihydropyrimidinyl benzazepine
EP3478321A4 (fr) 2016-06-30 2020-04-22 Oncorus, Inc. Administration par un virus oncolytique pseudotypé de polypeptides thérapeutiques
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP3554542A1 (fr) 2016-12-19 2019-10-23 H. Hoffnabb-La Roche Ag Polythérapie avec des agonistes de 4-1bb (cd137) ciblés
JP7247091B2 (ja) 2016-12-20 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
MX2019007795A (es) 2017-01-03 2019-08-16 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
WO2018178074A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécules trimériques de liaison à l'antigène spécifiques pour récepteur de co-stimulation du tnf
ES2928718T3 (es) 2017-04-03 2022-11-22 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
JP6997209B2 (ja) 2017-04-04 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０およびｆａｐに特異的に結合することができる新規な二重特異性抗原結合分子
MX2019011910A (es) 2017-04-05 2020-01-09 Hoffmann La Roche Anticuerpos biespecificos de union especifica a pd1 y lag3.
WO2018189220A1 (fr) 2017-04-13 2018-10-18 F. Hoffmann-La Roche Ag Immunoconjugué d'interleukine -2, agoniste de cd40 et facultativement un antagoniste de liaison de l'axe pd -1 destiné à être utilisé dans des méthodes de traitement du cancer
US11883503B2 (en) 2017-09-25 2024-01-30 Dingfu Biotarget Co., Ltd. Methods and compositions for cancer treatment
EP3687546A4 (fr) 2017-09-26 2022-01-26 The Trustees Of The University Of Pennsylvania Compositions et procédés pour traiter une maladie cardiaque par des immunothérapies à lymphocytes t redirigés
CA3079036A1 (fr) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Polytherapie avec des agonistes de ox40 cibles
EP3703746A1 (fr) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Nouvelles molécules de liaison à l'antigène contenant un trimère de ligands de la famille du tnf
US12227594B2 (en) 2017-11-01 2025-02-18 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
CN109796532B (zh) * 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用
EP3502140A1 (fr) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Thérapie de combinaison d'agonistes d'icos ciblés contre la tumeur avec des molécules bispécifiques à cellules t
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
US11896643B2 (en) * 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
BR112020015568A2 (pt) 2018-03-13 2020-12-29 F. Hoffmann-La Roche Ag Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
EP3773911A2 (fr) 2018-04-04 2021-02-17 Xencor, Inc. Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
WO2019197600A1 (fr) 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Molécules de liaison à l'antigène ciblant her2 comprenant 4-1bbl
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
SG11202011139YA (en) * 2018-05-16 2020-12-30 Dragonfly Therapeutics Inc Protein binding nkg2d, cd16 and a fibroblast activation protein
EP3818082A1 (fr) * 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Nouvelles molécules de liaison à l'antigène 4-1bb bispécifiques
PH12021500024A1 (en) 2018-10-01 2022-05-02 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-fap clone 212
JP2022511396A (ja) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
EP3898682A1 (fr) 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
TW202030204A (zh) 2018-12-21 2020-08-16 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之超促效cd28抗原結合分子
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
EP3990477A1 (fr) 2019-06-26 2022-05-04 F. Hoffmann-La Roche AG Fusion d'un anticorps se liant à cea et 4-1bbl
CN114531878A (zh) 2019-06-27 2022-05-24 豪夫迈·罗氏有限公司 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
EP3763726A1 (fr) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
CN118930608A (zh) 2019-07-08 2024-11-12 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
BR112022000122A2 (pt) 2019-07-08 2022-04-26 3B Pharmaceuticals Gmbh Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos
WO2021061778A1 (fr) 2019-09-23 2021-04-01 The Trustees Of The Univeristy Of Pennsylvania Perturbation de tissus tumoraux par ciblage d'une protéine d'activation des fibroblastes (fap)
AU2020352986A1 (en) * 2019-09-23 2022-03-31 The Trustees Of The University Of Pennsylvania Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (FAP)
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
KR20220107251A (ko) 2020-01-09 2022-08-02 에프. 호프만-라 로슈 아게 새로운 4-1bbl 삼량체-함유 항원 결합 분자
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
TW202207975A (zh) 2020-05-11 2022-03-01 瑞士商赫孚孟拉羅股份公司 使用經修飾之ｐｂｍｃ及免疫結合體之組合療法
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
TW202216769A (zh) 2020-06-23 2022-05-01 瑞士商赫孚孟拉羅股份公司 靶向ｈｅｒ２的激動性ｃｄ２８抗原結合分子
WO2021260064A1 (fr) 2020-06-25 2021-12-30 F. Hoffmann-La Roche Ag Molécules bispécifiques de liaison à l'antigène anti-cd3/anti-cd28
WO2022007283A1 (fr) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 Kit et méthode de diagnostic d'une maladie associée à une expression de fap anormale, et support de stockage lisible par ordinateur
WO2022018178A1 (fr) 2020-07-24 2022-01-27 F. Hoffmann-La Roche Ag Procédé d'expression de fusion anticorps-multimère
US20230295258A1 (en) 2020-08-11 2023-09-21 Kanaph Therapeutics Inc. Fusion protein comprising il-12 and anti-fap antibody, and use thereof
JP2023549316A (ja) 2020-11-16 2023-11-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
EP4274835A1 (fr) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation des fibroblastes et leur utilisation
EP4050018A1 (fr) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
EP4314032A1 (fr) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Polypeptides activés par une protéase
EP4323531A1 (fr) 2021-04-12 2024-02-21 Affinia Therapeutics Inc. Aav recombinant pour le traitement d'une maladie neurale
WO2023113806A1 (fr) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Vaa recombinant pour le traitement d'une maladie neurale
US20240199762A1 (en) * 2021-04-23 2024-06-20 Philogen S.P.A Anti-fibroblast activation protein antibodies
JP2024515788A (ja) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスｄｎａベクター及びその使用
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4367145A4 (fr) * 2021-07-09 2025-06-11 Imaginab, Inc. Nouvelles séquences d'anticorps à des fins de diagnostic et de thérapie
EP4148067A1 (fr) 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Procédé d'expression d'une fusion anticorps-multimère
EP4426735A1 (fr) 2021-11-01 2024-09-11 F. Hoffmann-La Roche AG Traitement du cancer à l'aide d'un anticorps bispécifique hla-a2/wt1 x cd3 et d'un agoniste de 4-1bb (cd137)
EP4448560A1 (fr) 2021-12-14 2024-10-23 F. Hoffmann-La Roche AG Traitement du cancer à l'aide d'un anticorps bispécifique hla-a2/mage-a4 x cd3 et d'un agoniste de 4-1bb (cd137)
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023153880A1 (fr) 2022-02-11 2023-08-17 주식회사 카나프테라퓨틱스 Composition pharmaceutique pour le traitement du cancer comprenant une protéine de fusion comprenant il-12 et un anticorps anti-fap et un agent anticancéreux
AU2023235112A1 (en) 2022-03-14 2024-10-17 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
CN114685673A (zh) * 2022-03-29 2022-07-01 深圳医爱健康管理有限公司 成纤维细胞激活蛋白抗体及使用方法
KR20230162310A (ko) 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
CN119604540A (zh) 2022-08-03 2025-03-11 南京维立志博生物科技股份有限公司 靶向FAP和TGFβ的抗体融合蛋白及其用途
WO2024074727A1 (fr) 2022-10-07 2024-04-11 Genethon Immunothérapie cellulaire par car-t anti-fap pour traiter des myopathies squelettiques
CN120344558A (zh) * 2022-12-08 2025-07-18 上海星赛生物科技有限公司 双特异性/多特异性抗体及其用途
WO2024184287A1 (fr) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Polythérapie à base d'un anticorps anti-egfrviii/anti-cd3 et d'un agoniste de 4-1bb ciblant une tumeur
WO2024188966A1 (fr) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps bispécifique anti-hla-g/anti-cd3 et d'un agoniste de 4-1bb (cd137)
WO2024208777A1 (fr) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Anticorps agonistes tout-en-un
WO2024208776A1 (fr) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Anticorps split agonistes
WO2024246086A1 (fr) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma
TW202504918A (zh) 2023-06-01 2025-02-01 瑞士商赫孚孟拉羅股份公司 靶向ｂｃｍａ及ｃｄ２８的雙特異性抗體
WO2024261013A1 (fr) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Polythérapie avec des agonistes du récepteur bêta de la lymphotoxine ciblant fap
WO2025129201A1 (fr) 2023-12-15 2025-06-19 Capstan Therapeutics, Inc. Anticorps anti-cd8 humanisés et leurs utilisations
CN118496382B (zh) * 2024-05-22 2025-01-07 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993005804A1 (fr) 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Anticorps f19 specifique contre les fibroblastes stromals actives et procedes pour son utilisation
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
EP1068241B1 (fr) 1998-04-02 2007-10-10 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (fr) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH Anticorps dirigé contre FAPalpha pouvant être produit avec une efficacité accrue
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (fr) 1999-10-19 2012-01-10 Tatsuya Ogawa L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
EP1268550A2 (fr) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Anticorps humains specifiques de fap-alpha
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
JP4936299B2 (ja) 2000-08-21 2012-05-23 メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ 磁場方向検出センサ
EP3690043A1 (fr) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Cellule produisant une composition d'anticorps
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8932825B2 (en) 2001-12-27 2015-01-13 Glycofi Inc. Method to engineer mammalian-type carbohydrate structures
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2481658A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fcy iiia
CA2481925A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Agent therapeutique pour les patients atteints du fc.gamma.riiia humain
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
ES2347325T3 (es) 2002-09-12 2010-10-28 Greenovation Biotech Gmbh Metodo de produccion de proteinas.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS51318B (sr) 2002-12-16 2010-12-31 Genentech Inc. Varijante imunoglobulina i njihova upotreba
US7781197B2 (en) 2002-12-20 2010-08-24 Greenovation Biotech Gmbh Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins
EP1587540B1 (fr) 2003-01-09 2021-09-15 MacroGenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
EP1585767A2 (fr) 2003-01-16 2005-10-19 Genentech, Inc. Banques de phages anticorps synthetiques
PL222219B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Komórka gospodarza i sposób wytwarzania polipeptydu w komórce gospodarza
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
MX337587B (es) 2003-11-05 2016-03-11 Glycart Biotechnology Ag Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas.
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (fr) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
DK1737891T3 (da) 2004-04-13 2013-03-25 Hoffmann La Roche Anti-p-selectin-antistoffer
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
WO2007064919A2 (fr) 2005-12-02 2007-06-07 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
EP1806365A1 (fr) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
CA2651567A1 (fr) 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison a squelettes optimises
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP5764127B2 (ja) * 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
PL2483310T3 (pl) 2009-09-29 2015-01-30 Roche Glycart Ag Bispecyficzne przeciwciała agonistyczne dla receptora śmierci
US8999342B2 (en) * 2009-10-02 2015-04-07 Ludwig Institute For Cancer Research, Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
US9011847B2 (en) 2010-08-13 2015-04-21 Roche Glycart, AG Anti-FAP antibodies and methods of use
ES2883371T3 (es) 2011-02-10 2021-12-07 Roche Glycart Ag Polipéptidos de interleucina 2 mutantes
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2848732T3 (es) 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
EP2882774B1 (fr) 2012-08-08 2018-10-03 Roche Glycart AG Protéines de fusion de l'interleukine-10 et leurs utilisations
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN105377893A (zh) 2013-05-07 2016-03-02 豪夫迈·罗氏有限公司 三聚体抗原结合分子
SG11201702805TA (en) 2014-10-08 2017-05-30 Hoffmann La Roche Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents

Also Published As

Publication number Publication date
CO6670523A2 (es) 2013-05-15
CL2016002116A1 (es) 2017-05-12
EA037977B1 (ru) 2021-06-18
US20160060357A1 (en) 2016-03-03
HUE036077T2 (hu) 2018-06-28
KR101673653B1 (ko) 2016-11-08
ZA201600552B (en) 2017-03-29
TWI599578B (zh) 2017-09-21
EA201790309A1 (ru) 2017-06-30
EA034742B1 (ru) 2020-03-16
AR082629A1 (es) 2012-12-19
CR20180142A (es) 2018-04-05
JP2020141674A (ja) 2020-09-10
JP7017599B2 (ja) 2022-02-08
EP3333194A1 (fr) 2018-06-13
TW201634480A (zh) 2016-10-01
HRP20172004T1 (hr) 2018-02-09
AR117658A2 (es) 2021-08-25
CN105884898B (zh) 2022-10-11
MX386437B (es) 2025-03-18
CA2806021C (fr) 2019-05-21
AU2011288487A1 (en) 2013-01-31
TW201206477A (en) 2012-02-16
NZ703653A (en) 2016-09-30
UA113712C2 (xx) 2017-02-27
PH12013500159A1 (en) 2013-02-18
JP2015180632A (ja) 2015-10-15
ES2655616T3 (es) 2018-02-20
MY184879A (en) 2021-04-29
CL2013000369A1 (es) 2014-08-08
EP3333194B1 (fr) 2021-03-17
JP5793568B2 (ja) 2015-10-14
US9011847B2 (en) 2015-04-21
PE20171512A1 (es) 2017-10-20
WO2012020006A3 (fr) 2012-04-12
MX358859B (es) 2018-09-05
CA2806021A1 (fr) 2012-02-16
PT2603530T (pt) 2018-01-09
KR20130066669A (ko) 2013-06-20
CR20130038A (es) 2013-04-29
PL2603530T3 (pl) 2018-03-30
BR112013003361B1 (pt) 2021-10-13
NZ605980A (en) 2015-01-30
CN103154038B (zh) 2016-05-11
ZA201600551B (en) 2018-05-30
HK1181402A1 (zh) 2013-11-08
US20200079873A1 (en) 2020-03-12
US20160060356A1 (en) 2016-03-03
UA112416C2 (uk) 2016-09-12
SG187746A1 (en) 2013-03-28
AU2011288487B2 (en) 2015-10-01
BR112013003361A2 (pt) 2017-06-13
IL224355B (en) 2019-03-31
EP2603530B1 (fr) 2017-11-08
DK2603530T3 (en) 2018-01-15
US10577429B2 (en) 2020-03-03
IL244000A0 (en) 2016-04-21
JP2013542714A (ja) 2013-11-28
KR20150039890A (ko) 2015-04-13
PH12013500159B1 (en) 2018-09-26
RS56702B1 (sr) 2018-03-30
CN105884898A (zh) 2016-08-24
ECSP13012440A (es) 2013-05-31
LT2603530T (lt) 2018-01-25
MX2013001268A (es) 2013-04-10
PE20131209A1 (es) 2013-10-25
PH12017501417A1 (en) 2020-07-13
TWI556827B (zh) 2016-11-11
MY175341A (en) 2020-06-19
US10253110B2 (en) 2019-04-09
KR101780131B1 (ko) 2017-09-19
NO2603530T3 (fr) 2018-04-07
CN103154038A (zh) 2013-06-12
EP2603530A2 (fr) 2013-06-19
US20120128591A1 (en) 2012-05-24
US11332545B2 (en) 2022-05-17
WO2012020006A2 (fr) 2012-02-16
SI2603530T1 (en) 2018-02-28
EA201300239A1 (ru) 2013-08-30
US20220281995A1 (en) 2022-09-08
US12286486B2 (en) 2025-04-29
JP2018099120A (ja) 2018-06-28
BR112013003361B8 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
MA34519B1 (fr) Anticorps anti-fap et procédés d'utilisation
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA34488B1 (fr) Composition pesticides
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA38632B1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UA110103C2 (uk) Модифікований туберкульозний антиген
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MY160552A (en) Low protein infant formula with increased essential amino acids
EP2427479A4 (fr) Anticorps et procédés d'utilisation de ceux-ci
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MY161868A (en) Anti-bv8 antibodies and uses thereof
EP2558496A4 (fr) Anticorps anti-polyubiquitine et procédés d'utilisation
EP2357199A4 (fr) Anticorps contre la région n-terminale de la chaîne de l'hémoglobine
FR2968561B1 (fr) Utilisation d'un anticorps dirige contre une proteine membranaire
EP2560658A4 (fr) Procédés d'amélioration de la cytotoxicité cellulaire dépendante des anticorps
EP2611928A4 (fr) Anticorps anti-c-met et procédés d'utilisation de ceux-ci